LONDON (The Thursday Times) — England’s health-cost watchdog has recommended offering a quick swallowed-sponge test to some people with persistent acid reflux, a move it says could catch oesophageal cancer earlier and ease pressure on hospital endoscopy services.
The draft guidance from the National Institute for Health and Care Excellence (NICE), published on Monday, backs two capsule sponge tests, Cytosponge, made by Medtronic, and EndoSign, made by Cyted Health. They would be offered to people with persistent gastro-oesophageal reflux disease and several risk factors who do not need an urgent suspected-cancer referral, and as an option for monitoring people already diagnosed with Barrett’s oesophagus.
How the test works
A patient swallows a small capsule attached to a thread. The capsule dissolves in the stomach, releasing a sponge that expands over about seven minutes. A healthcare professional then pulls the sponge back up by the thread, and it collects cells from the lining of the oesophagus on the way. The sample goes to a laboratory, and anyone whose result points to possible cancer or Barrett’s oesophagus is referred for an endoscopy to confirm it.
The tests need no sedation and can be done in GP surgeries and community diagnostic centres rather than in hospital. One trained healthcare professional can carry one out, whereas an endoscopy requires at least two nurses and an endoscopist. About 95 in 100 people can swallow the capsule after one or more attempts. Some people may have temporary discomfort or a sore throat afterwards, and serious side effects are rare.
Why it matters
Barrett’s oesophagus, in which the cells lining the lower food pipe change, affects an estimated 1 to 2 percent of adults and is more common in people with long-term reflux. It raises the risk of oesophageal cancer, although most people with the condition will not develop it. The cancer is much harder to treat when found late.
“Capsule sponge tests offer a quick and less invasive way to detect concerning changes associated with oesophageal cancer or Barrett’s oesophagus, helping to identify people who should go on to have further tests and treatment,” said Jonathan Benger, NICE’s chief executive. Demand for endoscopy is high, and in some areas people with Barrett’s are not checked as often as current guidance recommends.
Peter Johnson, NHS England’s national clinical director for cancer, said thousands of people had already benefited from the test through pilots, and that an easier check could help the health service find cancers earlier.
What happens next
NICE cautions that no diagnostic test, including endoscopy, finds every case, so people with a negative sponge result should be told when to seek further help. Comments on the draft can be sent to NICE until 7 December. Its independent committee meets again on 16 December, and final guidance is due in February 2027. If it is confirmed, the NHS in England will have to start offering the tests where they are the most suitable option.
The recommendations are the first produced under a new National HealthTech Access Programme, which assesses medical devices and diagnostic tests for routine use across the NHS. People with long-lasting heartburn or reflux should speak to their GP.



